Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients

American Journal of Kidney Diseases

Volumn 32, Issue 1, 1998, Pages 107-114

  Bologa, Roxana M ^a,b   Levine, Daniel M ^a   Parker, Thomas S ^a   Cheigh, Jhoong S ^a   Serur, David ^a   Stenzel, Kurt H ^a   Rubin, Albert L ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Rogosin Kidney Center   (United States)

Author keywords

Acute phase response; Albumin; Cholesterol; Cytokine; End stage renal disease; Hemodialysis; Inflammation

Indexed keywords

INTERLEUKIN 6; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DISEASE MARKER; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 0031808267     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9669431     Document Type: Article

References (31)

1. US Renal Data System, USRDS 1995, Annual Data Report, the National Institutes of Health, National Institute of Diabetes and Digestive Diseases and Kidney Diseases, Bethesda, MD, April 1995. Am J Kidney Dis 26:S69-S84, 1995
2. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
3. Churchill DN, Taylor DW, Cook RJ, Al E: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214-234, 1992
4. Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 44:115-119, 1993
5. Collins AJ, Ma JZ, Umen A, Keshaviah P: Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 23:272-282, 1993
6. Avram MM, Mittman N, Bonomini L, Chattopadhyay J, Fein P: Markers for survival in dialysis: A seven-year prospective study. Am J Kidney Dis 26:209-219, 1995
7. Kaysen GA, Frazier TS, Depner TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29:658-668, 1997
8. Trznadel K, Luciak M, Paradowski M, Kubasiewicz-Ujma B: Hemodialysis and the acute-phase response in chronic uremic patients. Int J Artif Organs 12:762-765, 1989
9. Docci D, Bilancioni R, Baldrati L, Capponcini C, Turci F, Feletti C: Elevated acute phase reactants in hemodialysis patients. Clin Nephrol 34:88-91, 1990
10. Honkanen E, Gronhagen-Riska C, Teppo AM, Maury CP, Meri S: Acute-phase proteins during dialysis: Correla-tions with serum interleukin-1 beta levels and different dialysis membranes. Nephron 57:283-287, 1991
11. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P: Balance between IL-1β, TNF-α and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 154:882-889, 1995
12. Herbelin A, Urena P, Nguyen AT, Zingraff J, Deschamps-Latscha B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39:954-960, 1991
13. Pereira BJG, Sundaram S, Snodgrass B, Hogan P, King AJ: Plasma liposaccharide binding protein and bactericidal/permeability increasing factor in CRF and HD patients. J Am Soc Nephrol 7:479-487, 1996
14. Nockher WA, Scherberich JE: Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int 48:1469-1476, 1995
15. Meur YLM, Fixe P, Aldigier JC, Leroux-Robert C, Praloron V: Macrophage colony-stimulating factor involvement in uremic patients. Kidney Int 50:1007-1012, 1996
16. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339-342, 1994
17. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, Monden M: Interleukin-6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin-6 transgenic mice. J Clin Invest 97:244-249, 1996
18. Mitch WE, Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Eng J Med 335:1897-1905, 1996
19. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JCL, Sloan BL, Barie PS, Rubin AL: Low lipid levels in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med 24:584-589, 1996
20. Doumas BT, Watson WA, Biggs HG: Albumin standards and the measurement of serum albumin with bromocresol green. Clin Chim Acta 31:87-96, 1971
21. Culp K, Flanigan M, Lowrie EG, Lew N, Zimmerman B: Modeling mortality risk in hemodialysis patients using laboratory values as time-dependent covariates. Am J Kidney Dis 28:741-746, 1996
22. Pekkanen J, Nissinen A, Variainen E, Salonen JT, Punsar S, Karvonen MJ: Changes in serum cholesterol level and mortality: A 30-year follow-up. The Finnish Cohorts of the Seven Countries study. Am J Epidemiol 139:155-165, 1994
23. Sherman ML, Spriggs DR, Arthur KA, Imanmura K, Frei E, Kufe DW: Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism. J Clin Oncol 6:344-350, 1988
24. Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE: Hypocholesteremia in patients treated with recombinant interleukin-2: Appearance of remnant-like lipoproteins. J Clin Oncol 7:1573-1577, 1989
25. Malmender CL, Lonte JF, Sculier JP, Dubios DY: Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced-cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis 73:173-180, 1988
26. Veldhuis GJ, Willemse PH, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, Mulder NH, de Vries EG: Toxicity and efficacy of escalating doses of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 13:2585-2595, 1995
27. Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pikkarainen J, Cantell K: Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68-73, 1982
28. Stoudemire JB, Garnick MB: Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. Blood 77:750-755, 1991
29. Nimer SD, Camplin RE, Golde DW: Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. J Am Med Assoc 260:3297-3300, 1988
30. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugiras JT, Bloembergen WE, Greer JW, Hakim RM: The dose of hemodialysis and patient mortality. Kidney Int 50:550-556, 1996
31. Hertel J, Lightfoot BO, Fincher ME, McConnell KR, Caruana RJ: Correlation between urea reduction rates and serum albumin levels in patients on hemodialysis. ASAIO J 41:M801-M804, 1995